Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.89)
# 47
Out of 5,146 analysts
41
Total ratings
71.79%
Success rate
61.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $25 → $22 | $10.93 | +101.28% | 2 | Feb 25, 2026 | |
| IBRX ImmunityBio | Maintains: Buy | $10 → $15 | $9.54 | +57.23% | 9 | Feb 23, 2026 | |
| IMNM Immunome | Initiates: Buy | $40 | $22.14 | +80.67% | 1 | Feb 12, 2026 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $5.96 | +285.91% | 3 | Feb 10, 2026 | |
| NBP NovaBridge Biosciences | Maintains: Buy | $7 → $9 | $3.28 | +174.39% | 1 | Feb 6, 2026 | |
| VSTM Verastem | Assumes: Buy | $18 | $5.83 | +208.75% | 1 | Feb 4, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $15 | $13.46 | +11.44% | 2 | Jan 26, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $58 | $46.97 | +23.48% | 2 | Jan 26, 2026 | |
| STRO Sutro Biopharma | Maintains: Neutral | $2 → $10 | $20.44 | -51.08% | 1 | Dec 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $10 → $4 | $0.64 | +525.00% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $60 | $41.38 | +45.00% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.11 | +530.63% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $20.75 | +92.77% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $7.77 | +414.80% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.18 | +344.02% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $55.62 | +88.78% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $56.99 | +31.60% | 4 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $10.10 | +147.52% | 2 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $6.02 | +265.45% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $15.22 | +31.45% | 1 | Aug 8, 2025 |
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $10.93
Upside: +101.28%
ImmunityBio
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $9.54
Upside: +57.23%
Immunome
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $22.14
Upside: +80.67%
Protara Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.96
Upside: +285.91%
NovaBridge Biosciences
Feb 6, 2026
Maintains: Buy
Price Target: $7 → $9
Current: $3.28
Upside: +174.39%
Verastem
Feb 4, 2026
Assumes: Buy
Price Target: $18
Current: $5.83
Upside: +208.75%
Erasca
Jan 26, 2026
Maintains: Buy
Price Target: $11 → $15
Current: $13.46
Upside: +11.44%
Scholar Rock Holding
Jan 26, 2026
Maintains: Buy
Price Target: $44 → $58
Current: $46.97
Upside: +23.48%
Sutro Biopharma
Dec 22, 2025
Maintains: Neutral
Price Target: $2 → $10
Current: $20.44
Upside: -51.08%
Werewolf Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.64
Upside: +525.00%
Dec 9, 2025
Maintains: Buy
Price Target: $20 → $60
Current: $41.38
Upside: +45.00%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.11
Upside: +530.63%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $20.75
Upside: +92.77%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $7.77
Upside: +414.80%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $5.18
Upside: +344.02%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $55.62
Upside: +88.78%
Sep 15, 2025
Reiterates: Buy
Price Target: $75
Current: $56.99
Upside: +31.60%
Sep 12, 2025
Reiterates: Buy
Price Target: $25
Current: $10.10
Upside: +147.52%
Aug 13, 2025
Reiterates: Buy
Price Target: $22
Current: $6.02
Upside: +265.45%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $15.22
Upside: +31.45%